Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes, looks like we are starting to get some eyes on us. I would think we will hear that we are moving into a preclinical study fairly soon. Good results from that would bring in some big funding for the next level.
NXEN mentioned alongside GWPH. It Seems things are starting to move.
https://www.advancemarketanalytics.com/reports/157542-global-cannabinoid-drugs-market
Wow! What the heck happened here today? Big news on the horizon.
I checked this stock out Saturday and wondered WTH happened. After doing some due diligence, I’ve determined this baby is going to climb like a mountain goat on jet fuel this week. What an amazing buying opportunity for this young company!!!!
We will see where this news leads us, I haven’t researched This guy yet.
9:00a ET 2/3/2022 - Globe Newswire
Nexien BioPharma Engages Dr. Benedikt Schoser as Advisor
Mentioned: NXEN
Nexien BioPharma Inc. (OTCQB: NXEN) ("Nexien" or the "Company") today announced that it has retained Dr. Benedikt Schoser as an advisor to the Company. Dr. Schoser, who has previously served as a scientific advisor to the Company, is senior consultant at the Friedrich-Baur Institute, Department of Neurology at the Ludwig-Maximilians-University of Munich, Germany's major national referral center for rare neuromuscular diseases, and is considered one of the world's top researchers in myotonia and the treatment of myotonic dystrophy. The Company also retained regulatory counsel and is initiating discussions with a pharmaceutical company to pursue formulation development. Richard Greenberg, Nexien's CEO and Chairman of the Board, stated, "We are excited to be establishing a team to address myotonic dystrophy and myotonia. The successful completion of our recent financing enables us to recommence our myotonic dystrophy research." Greenberg added, "Nexien has already been granted a United States patent for the treatment of dystrophies and myotonia and looks forward to benefiting from the team's knowledge regarding myotonic dystrophy, while seeking to advance a drug development strategy to treat myotonic dystrophy and myotonia."
Looks like we are back In business. Up to $1 million possibly. I do know they’ve wanted to get that initial money to kick something off in Germany so hopefully the pieces come together.
I feel like it’s a good industry to hold a position in. A company I work with was recently hacked and had to pay $750,000.00 to an unknown Russian hacker. This was just in December. This company that was hacked is not huge by any means. However, it showed me how easy it was for this to happen.
When the owners asked the hackers how they know they’ll follow through by not releasing their information, the hackers said,” we are honest thieves, you have nothing to worry about.” Haha That is the truth, I know the three partners personally who had to send the money.
I was in Hawaii a couple weeks ago reading your posts and actually felt the same way! FML By the way, no ice required in the Bloody Mary’s today, it’s -17 ??
I’ve been here since mid November quietly buying. I’m hoping for an amazing 2022 also!
Let the excitement begin for 2022!
They haven’t started phase 2. Read the December PR where they say that they are procuring permits yet.
Included in the patent PR written in December, OWCP talks about procuring the necessary permits for performing the efficacy study. These permits for the study are state IRB, institute IRB, liscense to purchase the cannibis for the study, liscense and contracts to hold cannabis for the manufacturing of the ointment etc. As you can see there is a lot to this. Long story short, their intentions with the patent in hand and an upcoming efficacy study is to move this into manufacturing. This would align with their “ differentiated in the market” approach they’ve taken. Hope this helps with your understanding of their approach with the cream. I can’t answer timelines for you, as I’m not sure how long it takes to procure these permits.
I agree, what a waste.
Yep, we need to get through the next 12 months!
I agree, these levels are really a steal if you have a longterm vision. They basically need a million dollars to get through another year and then a 5 million dollar investor once their drug enters orphan drug status. I have the patience to wait for this one to develop.
3 months ago they reported an acceptance of a patent application and were hopeful it would be granted in the coming months. We shall see if a granted patent brings some liquidity into this stock. Expect a PP announcement in the near future. Unfortunately with the stock price that’s probably not a good idea!
I think you’re right! For now it’s a dead stock it seems! I can’t figure out if I should buy more because it could climb like a mountain goat on jet fuel, or if they are closing their doors and I’m going to loose it all! Ha
Looking into this 8-k a little. I’m guessing we will see some sort of partnership/liscensing/merger deal due to their line of pet health care. A possible way to start generating revenue. Just my opinion of course.
I’ve owned that one for awhile:) thank you!
I agree, doesn’t seem like a good value at these levels. I think it’s reasonable to assume a deal between the two companies because they stated what they were doing with the sold shares. I don’t remember in previous investments sellers stating where their sold funds are going, do you?
Sold and bought into another company for partnership or liscensing deal possibly. We will see if their is an announcement next week.
I seen all that, really wasn’t sure if news will be coming next week regarding some sort of partnership between the two companies. Or if it’s just a large shareholder moving their investment around.
I’m not sure what this 8-k means, if anything at all really.
Pretty much!
He bought anywhere from .18 to .40 cents so he took a bath on it.
Share holder I know that use to own over 500,000 shares and is now down to 100,000 he claims he’s keeping. He’s been selling over the past 3 weeks he tells me. So that was actually a lot with this small float.
8-k was issued late yesterday.
https://www.otcmarkets.com/filing/html?id=13286903&guid=JdetUHDnGucrx3h
That’s a pretty professionally done investor presentation they did. Well done NXEN!
Living in Minnesota under blizzard conditions today makes me appreciate your name! I need a beach!
I agree with your comments, I’m going to buy more again. I bought a sizable amount at .18 and will probably pick up the same amount of shares again and then not do the PP deal if and when that happens. I’m able to hold longterm so it’s an easy decision for me. It might dip more, but longterm with such a low float this is a gem.
I’m checking out of I hub. Good luck to all!
That’s what they’re going to do? A 1:500 split? Read the 8-k, it’s just an open ended figure so they’re not held accountable to their real figure if and when it ever comes out in 2019. The investor and owners will have the last say in this game of poker. This is not an uncommon thing in the biopharma industry. Everyone should buck up, shut up, and vote accordingly.
So what does this merger really mean for our SP would you suspect?
If this proposal is approved, our Board of Directors would have the authority to effect one reverse stock split at such time as our Board of Directors shall determine, in its sole discretion, during the Company’s 2019 fiscal year ending December 31, 2019. Our Board of Directors believes that approval of a proposal providing our Board of Directors with this generalized grant of authority with respect to setting the split ratio, rather than mere approval of a pre-defined reverse stock split, will give our Board of Directors the flexibility to set the ratio in accordance with current market conditions and therefore allow our Board of Directors to act in the best interests of the Company and our stockholders.
In determining the ratio following the receipt of stockholder approval, our Board of Directors may consider, among other things, factors such as:
? the historical trading price and trading volume of our Common Stock;
? the then-prevailing trading price and trading volume of our Common Stock and the anticipated impact of the reverse stock split on the trading market for our Common Stock;
? the number of shares of our Common Stock then outstanding, and the number of shares of Common Stock issuable upon exercise of options and warrants then outstanding;
? the anticipated impact of a particular ratio on our ability to reduce administrative and transactional costs;
? prevailing general market and economic conditions; and
? the initial listing criteria of The Nasdaq Capital Market.
That’s not how it reads. The 8-k reads you will receive your proxy at or around feb 18th. All dates are blanked out as far as the meeting in New York goes. But, that’s pretty irrelevant, we are all in for a ride that could end up anywhere. Look for more information possibly next week.
The 5 million investor/ toxic loan whatever people want to call it owned on the open market already 7,776,784 shares previous to the announcement of him investing back In May. The recent 8-k announced he/she sold 7,376,090 shares through the convertible shares. Them numbers are very close to each other. Don’t know if that means anything, but they are strangely close to each other.
I agree with that statement. Problem is or could be if they don’t announce it before everyone turns their proxy in they probably won’t get their wish.
Again, science/Jv deal trumps everything.
I call it the truth, but you can twist it however you please. Fact is science and revenue news will trump all this discussion.
Our new CFO went through not one, but two reverse stock splits while at ROSG to maintain a price level to stay on the Nasdaq. ROSG science didn’t come home and the SP fell, until ultimately they filed bankruptcy. Let’s hope for better science!
They’re going to let it tank til their people get in and retail gets out. Then drop the big news before people fill their proxy out...... haha I really have no clue what to make of this so that’s my story! Don’t invest by it!
Did your two companies announce large catalyst during that time frame?